Sustained Benefit at 2 Years for Covered Stents Versus Bare-Metal Stents in Long SFA Lesions: The VIASTAR Trial

Abstract

At 24-month, this trial in PAD patients with long femoropopliteal lesions demonstrated a significantly improved primary patency rate for heparin-bonded covered stents compared to BMS, however, without a significant impact on clinical outcomes and TLR rate (Reg. Nr. ISRCTN48164244).

SCAI appropriate use criteria for peripheral arterial interventions: An update

“…The 1‐year patency in the VIASTAR group was 70.8% by intention to treat with no statistical advantage over the BMS group (55.1%, P = 0.11), but when analyzed by treatment received, the covered stent's 1‐year patency was 78.1%, which was superior to BMS (53.5%, P = 0.009) . The patency rates for the covered stent fell considerably at 2 years (63.1%) and even further at 3 years (24.2%) .…”

Three-year outcome of the heparin-bonded Viabahn for superficial femoral artery occlusive disease

“…[3][4][5][6] The randomized VIASTAR trial (Viabahn endoprosthesis with Propaten bioactive surface vs bare nitinol stent in the treatment of long lesions in SFA occlusive disease) comparing the heparin-bonded Viabahn with baremetal stents proved the superiority of the Viabahn over bare-metal stents at 24 months. 7 There was, however, no significant impact on clinical outcome and target revascularization rate. Recently, the performance and safety of the 25-cm-long heparin-bonded Viabahn were assessed in TransAtlantic Inter-Society Consensus II (TASC II) type C and D lesions, showing 1-year primary and secondary patency rates of 67.0% and 96.9%, respectively.…”

SCAI consensus guidelines for device selection in femoral‐popliteal arterial interventions

“…In long (20 cm) lesions, covered grafts had a significantly higher patency at 12 months (71% vs. 37%, P 5 0.01) [66]. At 24 months, Viabahn grafts had greater primary patency compared to BMS, however, without a significant impact on TLR rate [67]. In the VIBRANT trial, at 3 years, primary patency rates were not significantly different between patients treated with the VIABAHN graft and those who received BMS (24.2% vs. 25.9%) [68].…”